A novel GLP-1/GIP/Gcg triagonist reduces cognitive deficits and pathology in the 3xTg mouse model of Alzheimer's disease

Hippocampus
Tian LiJin-Shun Qi

Abstract

Type 2 diabetes mellitus (T2DM) is an important risk factor for Alzheimer's disease (AD). Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) have been identified to be effective in T2DM treatment and neuroprotection. In this study, we further explored the effects of a novel unimolecular GLP-1/GIP/Gcg triagonist on the cognitive behavior and cerebral pathology in the 7-month-old triple transgenic mouse model of AD (3xTg-AD), and investigated its possible electrophysiological and molecular mechanisms. After chronic administration of the GLP-1/GIP/Gcg triagonist (10 nmol/kg bodyweight, once daily, i.p.) for 30 days, open field, Y maze and Morris water maze tests were performed, followed by in vivo electrophysiological recording, immunofluorescence and Western blotting experiments. We found that the chronic treatment with the triagonist could improve long-term spatial memory of 3xTg-AD mice in Morris water maze, as well as the working memory in Y maze task. The triagonist also alleviated the suppression of long-term potentiation (LTP) in the CA1 region of hippocampus. In addition, the triagonist significantly reduced hippocampal pathological damages, including amyloid-β (Aβ) and phosphorylated ta...Continue Reading

References

Jun 1, 1996·Behavioural Brain Research·I A Cook, A F Leuchter
Nov 1, 1996·Diabetologia·A OttM M Breteler
Mar 7, 2002·Trends in Molecular Medicine·Hagit Eldar-Finkelman
Aug 1, 2002·Proceedings of the National Academy of Sciences of the United States of America·Kirsten G KjelstrupMay-Britt Moser
Oct 26, 2002·Science·Dennis J Selkoe
Jan 14, 2003·Seminars in Cell & Developmental Biology·Jonathan Flint
Jul 1, 2004·Neuroscience and Biobehavioral Reviews·D M BannermanJ Feldon
Aug 4, 2004·Psychoneuroendocrinology·Christian BenedictWerner Kern
Feb 18, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jenny NybergPeter S Eriksson
Oct 24, 2006·Neuroscience and Biobehavioral Reviews·L Giménez-LlortA Fernández-Teruel
Jan 24, 2007·The European Journal of Neuroscience·Claudie HooperSimon Lovestone
Feb 20, 2007·Pharmacology & Therapeutics·Máire E Doyle, Josephine M Egan
May 5, 2007·Diabetes Research and Clinical Practice·Jongsoon Lee, Myung-Sunny Kim
May 19, 2007·Journal of Neuroscience Research·Jenny NybergPeter S Eriksson
Jul 31, 2007·Neurobiology of Disease·Lani K ClintonFrank M LaFerla
Oct 9, 2007·Brain Research Reviews·Lin Li, Christian Hölscher
Feb 22, 2008·Neural Plasticity·Allan V Kalueff, Dennis L Murphy
Feb 4, 2009·Proceedings of the National Academy of Sciences of the United States of America·Fernanda G De FeliceWilliam L Klein
Feb 19, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Benedict J KolberLouis J Muglia
May 1, 2010·Nature Reviews. Drug Discovery·Martin Citron
Feb 3, 2011·British Journal of Clinical Pharmacology·Kawser AkterRobert B Raffa
Apr 29, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Paula L McCleanChristian Hölscher
May 21, 2011·The Journal of Pathology·Ying LiuCheng-Xin Gong
Jun 23, 2011·Journal of Alzheimer's Disease : JAD·Diana F F SilvaSandra M Cardoso
Dec 30, 2011·Molecular Neurobiology·Helgi B SchiöthChristian Benedict
Oct 5, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Tao MaEric Klann
Jan 2, 2013·European Journal of Pharmacology·Vadivel Parthsarathy, Christian Hölscher
Apr 23, 2013·Alzheimer's Research & Therapy·Emilie Faivre, Christian Hölscher

❮ Previous
Next ❯

Citations

Jun 19, 2018·Expert Opinion on Therapeutic Targets·Mahip K VermaKumar V S Nemmani
Nov 28, 2018·Expert Opinion on Investigational Drugs·Antoni CaminsJaume Folch
Mar 2, 2019·Expert Opinion on Drug Discovery·Mar QuiñonesOmar Al-Massadi
Mar 17, 2020·Expert Opinion on Investigational Drugs·Christian Hölscher
May 16, 2020·Expert Opinion on Investigational Drugs·Elliot J GlotfeltyNigel H Greig
Oct 27, 2018·Frontiers in Endocrinology·Silvano Paternoster, Marco Falasca
Apr 10, 2020·F1000Research·Josh ReedVenkateswarlu Kanamarlapudi
Jun 9, 2018·International Journal of Molecular Sciences·Yongfeng ZhangDi Wang
Jan 15, 2021·Molecular Neurodegeneration·Jeffrey Cummings
Jan 24, 2021·Molecular Neurobiology·Anit Tyagi, Subbiah Pugazhenthi
Jun 26, 2021·World Journal of Diabetes·Milagros RojasValmore Bermúdez
Jul 3, 2021·Expert Opinion on Investigational Drugs·Jonathan FlintoffThomas Hj Burne
Jul 31, 2021·Frontiers in Cell and Developmental Biology·Ruxin XieXiaotang Fan
Aug 10, 2019·ACS Pharmacology & Translational Science·Elliot J GlotfeltyNigel H Greig
Dec 24, 2021·Expert Opinion on Investigational Drugs·Andreas P KatsenosKonstantinos I Tsamis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Animal Models

Alzheimer's disease is a neurodegenerative disease which can be studied using various experimental systems. This feed focuses on animal models used for Alzheimer's disease research.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.